Referencias►
1.
Prasad AN, Stafstrom CF, Holmes GL. Alternative epilepsy therapies: the ketogenic diet, immunoglobulins, and steroids.
Epilepsia.
1996;37:S81 - S95.
2.
Vining EPG, Freemen JM, Ballaban-Gil K, et al. A multicenter study of the efficacy of the ketogenic diet.
Arch Neurol.
1998;55:1433 - 1437.
3.
Freeman JM, Vining EP, Pillas DJ, et al. The efficacy of the ketogenic diet-1998: a prospective evaluation of intervention in 150 children.
Pediatrics.
1998;102:1358 - 1363.
4.
Neelam GK, Koehler AN, McGhee B, et al. The ketogenic diet in refractory epilepsy: the experience of Children's Hospital of Pittsburgh.
Clinical Pediatrics.
2000;39:153 - 159.
5.
Mak SC, Chi CS, Wan CJ. Clinical experience of ketogenic diet on children with refractory epilepsy.
Acta Paediatr Taiwan.
1999;40:97 - 100.
6.
Lefevre F, Aronson N. Ketogenic diet for the treatment of refractory epilepsy in children: a systematic review of efficacy.
Pediatrics.
2000;105:E46.
7.
Wing RR, Vazquez JA, Ryan CM. Cognitive effects of ketogenic weight-reducing diets.
Int J Obes Relat Metab Disord.
1995;19:811 - 816.
8.
Woody RC, Steele RW, Knapple WL, et al. Impaired neutrophil function in children with seizures treated with the ketogenic diet.
J Pediatr.
1989;115:427 - 430.
9.
Hassan AM, Keene DL, Whiting SE, et al. Ketogenic diet in the treatment of refractory epilepsy in childhood.
Pediatr Neurol.
1999;21:548 - 552.
10.
Herzberg GZ, Fivush BA, Kinsman SL, et al. Urolithiasis associated with the ketogenic diet.
J Pediatr.
1990;117:743 - 745.
11.
Swink TD, Vining EP, Freeman JM. The ketogenic diet: 1997.
Adv Pediatr.
1997;44:297 - 329.
12.
Bloom WL, Azar GJ. Similarities of carbohydrate deficiency and fasting: weight loss, electrolyte excretion, and fatigue.
Arch Intern Med.
1963;112:333 - 337.
13.
Berry-Kravis E, Booth G, Taylor A, et al. Bruising and the ketogenic diet: evidence for diet-induced changes in platelet function.
Ann Neurol.
2001;49:98 - 103.
14.
Ballaban-Gil K, Callahan C, O'Dell C, et al. Complications of the ketogenic diet.
Epilepsia.
1998;39:744 - 748.
15.
Berkowitz VJ. A view on high-protein, low-carb diets [Letter response].
J Am Diet Assoc.
2000;100:1300, 1302 - 1303.
16.
Kishi T, Fujita N, Eguchi T, et al. Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy.
J Neurol Sci.
1997;145:109 - 112.
17.
Reynolds EH. Mental effects of anticonvulsants, and folic acid metabolism.
Brain.
1968;91:197 - 214.
18.
Hendel J, Dam M, Gram L, et al. The effects of carbamazepine and valproate on folate metabolism.
Acta Neurol Scand.
1984;69:226 - 231.
19.
Berg MJ, Stumbo PJ, Chenard CA, et al. Folic acid improves phenytoin pharmacokinetics.
J Am Diet Assoc.
1995;95:352 - 356.
20.
Lewis DP, Van Dyke DC, Willhite LA, et al. Phenytoin-folic acid interaction.
Ann Pharmacother.
1995;29:726 - 735.
21.
Lewis DP, Van Dyke DC, Stumbo PJ, et al. Drug and environmental factors associated with adverse pregnancy outcomes. Part I: Antiepileptic drugs, contraceptives, smoking, and folate.
Ann Pharmacother.
1998;32:802 - 817.
22.
Arenz A, Klein M, Fiehe K. Occurrence of neurotoxic 4'-O-methylpyridoxine in Ginkgo biloba leaves, ginkgo medications and Japanese ginkgo food.
Planta Med.
1996;62:548 - 551.
23.
Said HM, Redha R, Nylander W. Biotin transport in the human intestine: inhibition by anticonvulsant drugs.
Am J Clin Nutr.
1989;49:127 - 131.
24.
Krause KH, Bonjour JP, Berlit P, et al. Biotin status of epileptics.
Ann N Y Acad Sci.
1985;447:297 - 313.
25.
Wahl TO, Gobuty AH, Lukert BP. Long-term anticonvulsant therapy and intestinal calcium absorption.
Clin Pharmacol Ther.
1981;30:506 - 512.
26.
Weinstein RS, Bryce GF, Sappington LJ, et al. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment.
J Clin Endocrinol Metab.
1984;58:1003 - 1009.
27.
Carter BL, Garnett WR, Pellock JM, et al. Effect of antacids on phenytoin bioavailability.
Ther Drug Monit.
1981;3:333 - 340.
28.
McElnay JC, Uprichard G, Collier PS. The effect of activated dimethicone and a proprietary antacid preparation containing this agent on the absorption of phenytoin.
Br J Clin Pharmacol.
1982;13:501 - 505.
29.
Hahn TJ, Hendin BA, Scharp CR, et al. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults.
N Engl J Med.
1972;287:900 - 904.
30.
Jubiz W, Haussler MR, McCain TA, et al. Plasma 1,25-dihydroxyvitamin D levels in patients receiving anticonvulsant drugs.
J Clin Endocrinol Metab.
1977;44:617 - 621.
31.
Brodie MJ, Boobis AR, Dollery CT, et al. Rifampicin and vitamin D metabolism.
Clin Pharmacol Ther.
1980;27:810 - 814.
32.
Williams C, Netzloff M, Folkerts L, et al. Vitamin D metabolism and anticonvulsant therapy: effect of sunshine on incidence of osteomalacia.
South Med J.
1984;77:834 - 836, 842.
33.
Cornelissen M, Steegers-Theunissen R, Kollee L, et al. Increased incidence of neonatal vitamin K deficiency resulting from maternal anticonvulsant therapy.
Am J Obstet Gynecol.
1993;168:923 - 928.
34.
Cornelissen M, Steegers-Theunissen R, Kollee L, et al. Supplementation of vitamin K in pregnant women receiving anticonvulsant therapy prevents neonatal vitamin K deficiency.
Am J Obstet Gynecol.
1993;168:884 - 888.
35.
Hug C, McGraw CA, Bates SR, et al. Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children.
J Pediatr.
1991;119:799 - 802.
36.
Chung S, Choi J, Hyun T, et al. Alterations in the carnitine metabolism in epileptic children treated with valproic acid.
J Korean Med Sci.
1997;12:553 - 558.
37.
Melegh B, Trombitas K. Valproate treatment induces lipid globule accumulation with ultrastructual abnormalities of mitochondria in skeletal muscle.
Neuropediatrics.
1997;28:257 - 261.
38.
Zelnik N, Fridkis I, Gruener N. Reduced carnitine and antiepileptic drugs: cause relationship or co-existence?
Acta Paediatr.
1995;84:93 - 95.
39.
Coulter DL. Carnitine deficiency in epilepsy: risk factors and treatment.
J Child Neurol.
1995;10(suppl 2):S32 - S39.
40.
Melegh B, Pap M, Morava E, et al. Carnitine-dependent changes of metabolic fuel consumption during long-term treatment with valproic acid.
J Pediatr.
1994;125:317 - 321.
41.
De Vivo DC, Bohan TP, Coulter DL, et al. L-carnitine supplementation in childhood epilepsy: current perspectives.
Epilepsia.
1998;13:1216 - 1225.
42.
Matsuda I, Ohtani Y. Carnitine status in Reye and Reye-like syndromes.
Pediatr Neurol.
1986;2:90 - 94.
43.
Camina MF, Rozas I, Gomez M, et al. Short-term effects of administration of anticonvulsant drugs on free carnitine and acylcarnitine in mouse serum and tissues.
Br J Pharmacol.
1991;103:1179 - 1183.
44.
Rodriguez-Segade S, de la Pena CA, Tutor JC, et al. Carnitine deficiency associated with anticonvulsant therapy.
Clin Chim Acta.
1989;181:175 - 181.
45.
Freeman JM, Vining EP, Cost S, et al. Does carnitine administration improve the symptoms attributed to anticonvulsant medications?: a double-blinded, crossover study.
Pediatrics.
1994;93(6 pt 1):893 - 895.
46.
Yarnell EY, Abascal K. An herbal formula for treating intractable epilepsy: a review of the literature.
Alt Compl Ther.
2000;6:203 - 206.
47.
Narita Y, Satowa H, Kokubu T, et al. Treatment of epileptic patients with the Chinese herbal medicine "saiko-keishi-to" (SK).
IRCS Med Sci.
1982;10:88 - 89.
48.
Nagakubo S, Niwa S, Kumagai N, et al. Effects of TJ-960 on Sternberg's paradigm results in epileptic patients.
Jpn J Psych Neur.
1993;47:609 - 619.
49.
Durelli L, Mutani R. The current status of taurine in epilepsy.
Clin Neuropharmacol.
1983;6:37 - 48.
50.
Marchesi GF, Quattrini A, Scarpino O, et al. Therapeutic effects of taurine in epilepsy: a clinical and polyphysiographic study [in Italian; English abstract].
Riv Patol Nerv Ment.
1975;96:166 - 184.
51.
Fukuyama Y, Ochiai Y. Therapeutic trial by taurine for intractable childhood epilepsies.
Brain Dev.
1982;4:63 - 69
52.
Fauteck JD, Schmidt H, Lerchl A, et al. Melatonin in epilepsy: First results of replacement therapy and first clinical results.
Biol Signals Recept.
1999;8:105 - 110.
53.
Akram M, Sullivan C, Mack G, et al. What is the clinical significance of reduced manganese and zinc levels in treated epileptic patients?
Med J Aust.
1989;151:113.
54.
Theodore WH, Hunter K, Chen R, et al. Transcranial magnetic stimulation for the treatment of seizures: A controlled study.
Neurology.
2002;59:560 - 562.
55.
Egger J, Carter CM, Soothill JF, et al. Oligoantigenic diet treatment of children with epilepsy and migraine.
J Pediatr.
1989;114:51 - 58.
56.
Stavem K, Kloster R, Rossberg E, et al. Acupuncture in intractable epilepsy: lack of effect on health-related quality of life.
Seizure.
2000;9:422 - 426.
57.
Kajiyama Y, Fujii K, Takeuchi H, et al. Ginkgo seed poisoning.
Pediatrics.
2002;109:325 - 327.
58.
Granger AS. Ginkgo biloba precipitating epileptic seizures.
Age Ageing.
2001;30:523 - 525.
59.
Gregory PJ. Seizure associated with Ginkgo biloba? [letter].
Ann Intern Med.
2001;134:344.
60.
Coleman M. Myoclonus in the young after 5-hydroxytryptophan [letter].
N Engl J Med.
1977;296:820.
61.
Hagan JJ, Hatcher JP, Slade PD. The role of 5-HT1D and 5-HT1A receptors in mediating 5-hydroxytryptophan induced myoclonic jerks in guinea pigs.
Eur J Pharmacol.
1995;294:743 - 751.
62.
Tatro D.
A to Z Drug Facts.
2nd ed. [book on CD-ROM]. St. Louis, Mo: Facts and Comparisons; 2000.
63.
Monostory K, Vereczkey L, Levai F, et al. Ipriflavone as an inhibitor of human cytochrome P450 enzymes.
Br J Pharmacol.
1998;123:605 - 610.
64.
Inoue F, Walsh RJ. Folate supplements and phenytoin-salicylate interaction.
Neurology.
1983;33:115 - 116.
65.
Bourgeois BF, Dodson WE, Ferrendelli JA. Interactions between primidone, carbamazepine, and nicotinamide.
Neurology.
1982;32:1122 - 1126.
66.
Vaddadi KS. The use of gamma-linolenic acid and linoleic acid to differentiate between temporal lobe epilepsy and schizophrenia.
Prostaglandins Med.
1981;6:375 - 379.
67.
Tyagi A, Delanty N. Herbal remedies, dietary supplements, and seizures.
Epilepsia. 2003;44:228 - 235.